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ABSTRACT
INTRODUCTION: Pancreatogenic diabetes develops in pa-
tients undergoing total pancreatectomy and complicates 
post-surgical management. The aim of this study was to 
compare parenteral nutrition (PN) with protocolled insulin 
treatment to intravenous glucose treatment after total pan-
createctomy.
METHODS: This was a retrospective study of 97 patients  
undergoing total pancreatectomy between 2009 and 2014. 
Patients were divided into a PN cohort (n = 57) and a glu-
cose cohort (n = 40). The PN cohort was given PN with one 
international unit (IU) rapid-acting insulin per 10 g of carbo-
hydrate. The glucose cohort was given a continuous 5% glu-
cose infusion with 2 IU rapid-acting insulin per 10 g of car-
bohydrate. Both cohorts were given insulin detemir 0.2 IU/
kg/day. 
RESULTS: Within the first 13 post-operative days, plasma 
glucose values were within the target range (4.0-10.0 
mmol/l) in the PN cohort more frequently than in the glu-
cose cohort (46% versus 42%, p = 0.01) without any in-
crease in hypoglycaemia. Non-infectious complications oc-
curred less frequently in the parenteral cohort than in the 
glucose cohort (23% versus 43%, p = 0.04). Infectious com-
plications occurred in 19% versus 33% of patients, respect-
ively (p = 0.14). The mean length of hospitalisation was 19.8 
± 12.7 versus 25.0 ± 21.5 days, p = 0.14.
CONCLUSIONS: After total pancreatectomy, PN with insulin 
treatment per protocol improves glycaemic control com-
pared with glucose infusion and reduces the number of 
non-infectious post-operative complications without in-
creasing hypoglycaemia.
FUNDING: none.
TRIAL REGISTRATION: not relevant.
Total pancreatectomy is mainly indicated for patients 
with pancreatic malignancy [1, 2]. The resulting pancrea-
togenic diabetes is characterised by hyperglycaemia, fre-
quent episodes of hypoglycaemia during insulin treat-
ment, but rarely by ketoacidosis [3, 4]. During insulin 
treatment after total pancreatectomy, patients sustain 
an increased risk of hypoglycaemia, especially during 
night time [3-5]. This susceptibility to hypoglycaemia 
may be aggravated by insufficient nutrition, leading to 
catabolism and glycogen depletion in the muscles and 
liver [3]. In addition to regulation of blood glucose, in-
sulin is a major anabolic hormone, which increases pro-
tein synthesis and enhances macrophage infiltration in 
wounds, thus promoting tissue repair after surgery [6, 
7]. Total pancreatectomy is a rare procedure performed 
by pioneers, while partial pancreatectomy is much more 
common. After partial pancreatectomy, hyperglycaemia 
within the first 24 hours is associated with an increased 
length of hospitalisation and an increased number of 
surgical complications [8, 9]. Post-operative parenteral 
nutrition (PN) is indicated where adequate enteral feed-
ing is not expected within seven days after surgery [10]. 
Therefore, PN might be beneficial after major surgery, 
such as total pancreatectomy, although an increased 
prevalence of post-operative infections has also been 
described [11], and fear of hyperglycaemia may also be 
a barrier for PN. Appropriate nutrition and insulin treat-
ment after total pancreatectomy is critical in these total-
ly insulin-depleted patients. However, prospective ran-
domised trials in this rare patient category are difficult 
to accomplish.
In our centre, the post-operative nutritional regi-
men after total pancreatectomy initially consisted of 
continuous intravenous glucose infusion based on the 
assumption that enteral feeding would be established 
within few days. However, for the majority of patients, 
this was not the case. In 2012, the post-operative nutri-
tional regimen was therefore changed to include PN 
with insulin treatment according to a newly developed 
local protocol. The aim of this study was therefore to 
evaluate PN with protocolled insulin treatment versus 
intravenous glucose treatment for its effect on glyc-




This retrospective study included 97 (92%) out of 106 
patients undergoing total pancreatectomy between De-
cember 2009 and November 2014 at the Department of 
Surgical Gastroenterology, Rigshospitalet, Copenhagen. 
Nine patients were excluded because their diabetes 
charts were unavailable. According to the post-operative 
nutritional regimen, patients were divided into two co-
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horts; the PN cohort (n = 57) including patients who had 
a total pancreatectomy from August 2012 to November 
2014 and the glucose cohort (n = 40) including patients 
who had total pancreatectomy between December 2009 
and July 2012. 
The PN cohort started PN (SmofKabiven, Fresenius 
Kabi, Hamburg, Germany) on the first post-operative 
day. PN was given at a constant infusion rate over 20 
hours per day. One international unit (IU) of rapid-acting 
insulin aspart (Novorapid, Novo Nordisk) per 10 g of car-
bohydrate was added to the PN. PN was administered 
according to preoperative body weight. Thus, patients 
received 125 g (40-50 kg), 187 g (51-70 kg), 250 g (71-90 
kg), or 313 g (> 90 kg) of carbohydrate per day. PN was 
terminated when the patient had a sufficient oral daily 
intake of at least 150 g of carbohydrates.
The glucose cohort was treated with continuous in-
travenous infusion of isotonic glucose 5%, which was ini-
tiated on the first post-operative day. The infusion rate 
was 60 ml/hour, which is consistent with a 72-g carbohy-
drate intake per 24-hour period. According to local prac-
tice, 2 IU of insulin aspart was added per 10 g of carbo-
hydrate. Only on various individual indications could 
patients initiate PN. Glucose infusion was terminated 
when a sufficient oral intake was restored. 
Both cohorts had a routine 24-hour post-operative 
stay at the intensive care unit, where they were given  
individually titrated glucose-insulin infusion. When 
transferred to the surgical ward, the patients initiated 
treatment according to the post-operative nutritional 
regimen described above. Plasma glucose was measured 
at least five times daily. In order to ensure basic insulin 
requirements, patients were given long-acting insulin 
detemir (Levemir, Novo Nordisk) 0.2 IU/kg/day divided 
into two doses. Supplementary doses of insulin aspart 
were given when plasma glucose values exceeded 10 
mmol/l. A meal bolus of insulin aspart (2 IU) was given 
when oral feeding was initiated along with protein en-
ergy drinks (2-4 IU). Supplementary digestive enzymes 
(Creon, Mylan) were given with every meal. 
Data sampling and management
Clinical data were obtained from the hospital records in-
cluding diabetes charts. Day 0 was defined as the day of 
surgery. The daily median plasma glucose level for each 
patient was calculated. Additionally, plasma glucose  
values were divided into five predefined intervals and 
the target range was defined as a plasma glucose be-
tween 4.0-10.0 mmol/l. Severe symptomatic hypoglyc-
aemia was defined as events requiring assistance from 
another person to restore normal glucose values [12]. 
Data regarding complications including mortality within 
the first 13 post-operative days were obtained from the 
surgical records and subsequently divided into the fol-
lowing categories: infectious complications, non-infec-
tious complications and major complications. Each  
cat egory consisted of a number of pre-defined and  
well-established post-surgical complications. Reopera-
tion was defined as intra-abdominal surgery requiring 
general anaesthesia excluding cases caused by wound 
infection or wound dehiscence. 
TABLE 1
Baseline characteristics of two cohorts undergoing total pancreatectomy given routine postoperative 
parenteral nutrition treatment or glucose infusion, respectively. 
Parenteral nutrition 
cohort (n = 57)
Glucose cohort 
(n = 40) p-value
Men/women, n 30/27 19/21 0.62
Age, yrs, mean ± SD 65.9 ± 9.7 65.1 ± 7.7 0.67
Weight, kg, mean ± SD 68.7 ± 2.0 72.8 ± 2.7 0.21
BMI, kg/m2, mean ± SD 23.5 ± 4.7 24.2 ± 5.3 0.51
Preoperative diabetes mellitus, n (%) 12 (21) 16 (40) 0.04
Current smokers, n (%) 20 (35) 11 (28) 0.55
Alcohol exceeding recommendationsa, n (%) 9 (16) 6 (15) 0.79
Histology, n (%) 0.09
Adenocarcinoma 48 (84) 28 (70) 
Intraductal papillary mucinous neoplasm   6 (11)   2 (5) 
Chronic pancreatitis   1 (1.8)   2 (5) 
Cystadenoma (serous/mucinous)   0   3 (7.5) 
Neuroendocrine tumour   1 (1.8)   1 (2.5)
Other   1 (1.8)   4 (10)  
Tumour limited to the pancreasb, n (%)   6 (12)   5 (15) 0.72
Tumour extending beyond the pancreasb, n (%) 44 (88) 29 (85)
Lymph node metastasisb, n (%) 37 (74) 27 (79) 0.57
Unilateral adrenalectomy, n (%) 5 (8.8) 0 (0) 0.05
SD = standard deviation.
a) Alcohol consumption exceeding the recommendation of The Danish Health Authority  
(women: 7 U/wk, men: 14 U/wk).
b) Tumour staging was performed in 50 and 34 patients, tumour staging included T1 and T2 or T3 and 
T4, staging according to the American Joint Committee on Cancer TNM staging system.
FIGURE 1
Median plasma glucose concentration during the first 13 post-operative 
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. -♦-: parenteral nutrition cohort; -□-: glucose cohort.
*) p < 0.05<
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Outcome measures
The primary outcome was glycaemic control, evaluated 
by distribution of plasma glucose levels < 4.0 mmol/l, 
4.0-10.0 mmol/l or > 10.0 mmol/l, and length of hospi-
talisation. Secondary outcome measures were incidence 
of complications within the first 13 post-operative days. 
Statistical analysis
Numerical variables are presented as mean ± standard 
deviation when regarded normally distributed, other-
wise as median and range. Dichotomous variables are 
presented as numbers and percentages. Student’s t test, 
the Mann-Whitney U-test and the chi-squared test were 
used as appropriate. p-values < 0.05 were considered 
significant. Statistical analyses were performed using 
SPSS Statistics 22 (IBM, Armonk, NY, USA). 
Trial registration: not relevant.
RESULTS
Study population
The demographic and clinical characteristics of the two 
cohorts including tumour staging were comparable, with 
the exception that preoperative diabetes occurred less 
frequently in the PN cohort than in the glucose cohort  
(p = 0.04) (Table 1). In the glucose cohort, 11 (28%) pa-
tients received PN with a median duration of three days 
within the first 13 post-operative days in addition to glu-
cose infusion, mostly in cases where post-operative 
complications caused a delay in achieving a sufficient 
oral intake. 
Glycaemic control
In the PN cohort, 3,312 plasma glucose measurements 
were registered during 754 observation days. Similarly, 
in the glucose cohort, 2,143 plasma glucose measure-
ments were registered during 553 observation days.  
The course of the plasma glucose followed a similar con-
figuration throughout the post-operative period in the 
two cohorts, without any clinically significant differences 
(Figure 1). More plasma glucose measurements were 
within the target range 4.0-10.0 mmol/l in the PN cohort 
compared to the glucose cohort (p = 0.01) (Table 2) 
without any difference in prevalence of severe symp-
tomatic hypoglycaemia (p = 0.10). No clinically signifi-
cant weight loss was seen in either cohort (Table 2). 
A sub-analysis was performed of the 32 patients 
who discontinued PN within the first 13 post-operative 
days. A pooled analysis of glucose data four days prior to 
and four days after discontinuation of PN revealed a me-
dian plasma glucose of 12.2 mmol/l and 8.4 mmol/l be-
fore and after discontinuation of PN, respectively (p < 
0.001) (Figure 2). The prevalence of biochemical hypo-
glycaemia (< 4.0 mmol/l) was 0.7% out of 613 measure-
ments before and 7.0% out of 591 measurements after 
discontinuation of PN (p < 0.001).
Post-operative complications
There were fewer non-infectious complications in the 
PN cohort than in the glucose cohort (23% versus 43%,  
p = 0.04), with wound dehiscence being the most preva-
lent complication in both groups. There was a smaller 
number of infectious complications and major complica-
tions in the PN cohort than in the glucose cohort, but 
the differences did not reach statistical significance. One 
patient in each cohort died within the first 14 days dur-
TABLE 2
Post-operative plasma glucose measurements, insulin treatment and postoperative complications for 
two cohorts following total pancreatectomy given routine parenteral nutrition treatment or glucose in-
fusion.
Parenteral nutrition 
cohort (n = 57)
Glucose cohort 
(n = 40) p-value
Plasma glucose measurements, n 3,312 2,143 0.33
Plasma glucose measurements/patient/24 h, n, 
median (range)
5 (2.5-8.0) 5 (2.0-6.0) 0.78
Plasma glucose measurements, n (%)
< 2.2 mmol/l        7 (0.2)     9 (0.4)   0.16
2.2-3.9 mmol/l    143 (4.3) 107 (5) 0.24
4.0-10.0 mmol/l 1,525 (46) 910 (42) 0.01
10.1-14.0 mmol/l    863 (26) 596 (28) 0.15
> 14.0 mmol/l    774 (23) 521 (24) 0.42
Insulin dose, IU/24 h at discharge, median (range)
Rapid-acting insulin   6.0 (0-15)   6.0 (0-16) 0.84
Long-acting insulin 16.0 (5-33) 18.0 (7-36) 0.22
Subtotal 22.0 (8-48) 24.5 (8-48) 0.41
Days on glucose 5% infusion, n, median (range) 2 (1-10) 8 (2-14) < 0.001
Days on parenteral nutrition, n, median (range) 8 (1-13) 0 (0-11) < 0.001
Patients with severe symptomatic hypoglycaemia, 
n, median (range)
8 (14) 11 (28) 0.10
Change in body weight, kg, mean ± SD 0.4 ± 3.9 0.5 ± 3.6 0.90
Infectious complications, n (%) 11 (19) 13 (33) 0.14
Surgical site infections   4 (7)   2 (5)
Abdominal abscess   3 (5)   2 (5)
Pneumonia   5 (9)   8 (20)
Sepsis   3 (5)   5 (13)
Non-infectious complications, n (%) 13 (23) 17 (43) 0.04
Anastomotic leak    4 (7)   4 (10)
Wound dehiscence   7 (12)   8 (20)
Gastrointestinal bleeding   0   3 (8)
Haemoperitoneum   1 (2)   0
Respiratory failure   2 (4)   2 (5)
Cardiac failure   0   1 (3)
Major complications, n (%) 12 (21) 15 (38) 0.08
Reoperation   3 (5)   7 (18)
Intensive care unit transfer   8 (14) 11 (28)
Interventional radiology   4 (7)   2 (5)
Length of hospitalisation, days, mean ± SD 19.8 ± 12.7 25.0 ± 21.5 0.14
Readmissions within 30 days after discharge, n 
(%)
12 (22) 3 (8) 0.07
SD = standard deviation. 
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ing hospitalisation due to post-operative complications 
unrelated to hypoglycaemia. No significant differences 
in length of hospitalisation or readmission rates were 
detected (Table 1).
DISCUSSION
After total pancreatectomy, PN with insulin treatment 
per protocol improves glycaemic control compared with 
glucose infusion and reduces the number of non-infec-
tious post-operative complications with no increase in 
hypoglycaemia. A non-significant reduction in length of 
hospitalisation was noted. Improved nutrition with PN 
was neither associated with incontrollable high blood 
glucose levels nor with a high prevalence of severe 
hypo glycaemia. PN and insulin per protocol offered 
slightly superior glycaemic control, but the median glu-
cose levels were high during PN treatment. Based on 
this observation, it may be advisable to increase the 
amount of rapid-acting insulin added to the PN to 2 IU 
per 10 g of carbohydrate, which can probably be done 
without compromising treatment safety substantially. 
We found a trend towards decreased prevalence of 
sepsis and other infectious complications during PN. This 
may be owed to the improved nutrition including add-
itional carbohydrate, protein and lipids within the first 
eight post-operative days in the PN cohort. Supple ment-
ary protein intake in the post-operative period has previ-
ously been shown to decrease the incidence of minor 
complications following surgery including wound infec-
tion [13]. However, our results contradict a previous lit-
erature review concluding that PN increases the risk of 
infectious post-operative complications [11]. Add ition-
ally, in one study, patients who underwent partial pan-
createctomy had a significant increase in infectious com-
plications when receiving PN [14]. However, these 
results may not be representative for the patients in the 
present study because, unlike patients undergoing total 
pancreatectomy, patients with partial pancreatectomy 
maintain endogenous glucagon and insulin production. 
The reduced number of non-infectious complications in 
the PN cohort could be a result of the improved post- 
operative nutritional status and higher levels of circulat-
ing insulin in these vulnerable patients. We registered a 
shorter length of hospitalisation in the PN cohort than in 
the glucose cohort. However, this finding was not statis-
tically significant, which might be due to the relatively 
small number of patients in the present study. 
The glycaemic control during transition from PN to 
oral nutrition is also described in this paper. Initiation of 
oral nutrition post-operatively is often complicated by 
nausea, vomiting, and diarrhoea, which may result in a 
limited food intake and increase the risk of hypoglyc-
aemia. To overcome this increased risk of hypoglyc-
aemia, the long-acting insulin detemir with low day-to-
day variability [15] was administered twice daily with a 
relatively low evening dose. Despite this strategy, the 
prevalence of hypoglycaemia rose tenfold when PN was 
discontinued, and reduction of the evening basal insulin 
dose was often necessary. At discharge, the total insulin 
dose was 22 IU/day corresponding to approximately 0.3 
IU/kg/day, i.e. roughly half of the requirements of pa-
tients with Type 1 diabetes. This is in accordance with 
previous observations in patients after total pancreat-
ectomy [1].
The use of continuous glucose infusion as the pri-
mary nutritional support before 2012 was based on the 
ASPEN guidelines and the expectation that most pa-
tients were able to initiate oral feeding within few days. 
However, our data demonstrate that sufficient oral 
feeding could not be expected within seven days, which 
supports the implementation of PN after total pancreat-
ectomy.
The sample size in this study was large for this rare 
type of surgery [1, 2, 5, 16-20]. All patients were treated 
by the same two surgeons, who used the same surgical 
FIGURE 2
Median plasma glucose concentration before and after discontinuation 
of parenteral nutrition for patients in the parenteral nutrition cohort pre-
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technique, which minimised the risk that a difference in 
the number of post-operative complications was a result 
of variation in the surgeons’ experience with the surgical 
procedure. Both cohorts were treated according to the 
same antibiotic regimen. All data were extracted and an-
alysed according to a predefined protocol, and data re-
garding the primary outcomes were deemed accessible 
and reliable. In this retrospective study, data relied on 
information collected from medical and surgical records, 
so other causes for the decline in post-operative compli-
cations cannot be excluded. The number of readmis-
sions was low in both cohorts, and larger studies are 
needed to evaluate any differences in readmission rate. 
Mortality during the first 13 post-operative days was 
comparable, and data on long-term survival were not in-
cluded. The higher rate of preoperative diabetes in the 
glucose cohort might reflect a decreased peripheral in-
sulin sensitivity leading to higher plasma glucose levels. 
Previously, total pancreatectomy was discredited 
and nearly abandoned because of morbidity and mortal-
ity due to unstable plasma glucose values [18]. The pre-
sent study and recent studies [17-19] indicate that total 
pancreatectomy can be performed safely when PN in 
combination with modern diabetes treatment is offered. 
Information from this study, which includes a detailed 
insulin protocol, may be of importance for future treat-
ment of patients after total pancreatectomy. 
CONCLUSIONS
After total pancreatectomy, PN with insulin per protocol 
improves glycaemic control compared to intravenous 
glucose infusion and reduces the number of non-infec-
tious post-operative complications. Importantly, treat-
ment with PN does not increase the number of infec-
tious post-operative complications or hypoglycaemia.
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